The Evolving Role of Biomarker Analysis in the Management of Advanced/Metastatic NSCLC
Treatment decisions for patients with advanced/metastatic non–small cell lung cancer (NSCLC) are driven to a large extent by biomarkers, and a steadily expanding array of targeted therapies in recent decades has significantly improved outcomes. The optimal strategy for biomarker testing, however, is not clear-cut, and the use of biomarker analysis is further complicated by the constantly changing therapeutic landscape. In this video roundtable series, Dr Trever Bivona is joined by Dr Collin Blakely and Dr Jonathan Riess for a discussion of how biomarker analysis can most effectively be used to inform treatment decisions in patients with advanced/metastatic NSCLC.
Video 1: Initial Testing Strategies
The MYLUNG consortium found that while most NSCLC patients had at least one biomarker test result prior to beginning first-line therapy, less than 50% had all five tests. In light of these findings, the panel discusses the importance of testing for multiple mutations at diagnosis as well as considerations for choosing liquid or tissue biopsies for either oncogene testing or immunotherapy response.
Up Next
About the Panel
Disclosures
Trever Bivona, MD, PhD, has disclosed no relevant financial disclosures.
Collin Blakely, MD, has disclosed the following relevant financial relationships:
Received research grant from: AstraZeneca; Novartis; Takeda; Mirati; Roche; Spectrum
Jonathan Riess, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Jansse; Blueprint; EMD Serano; Daiichi Sankyo; BMS; Beigene; Turning Point
Received research grant from: Merck; Novartis; Spectrum; Revolution Medicines; AstraZeneca